Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Severe hemophilia (defined as \< 1% factor activity level)~* Infection with the hepatitis C virus (HCV) with underlying hemophilia~* Males 18 years of age and above~* Have not been previously treated with an interferon~Exclusion Criteria:~* Not infected with the hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Chronic liver disease caused by any disease other than chronic HCV infection~* Presence of Bethesda inhibitor~* Current evidence of or history of portal hypertension

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: Genotype-2,-3 (Lambda/RBV/DCV) (Type: EXPERIMENTAL): Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 12 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 12 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks
- Cohort B: Genotype-1b,-4 (Lambda/RBV/DCV) (Type: EXPERIMENTAL): Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 24 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 24 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).